Business Restructuring Charges (Tables)

12 Months Ended

Sep. 30, 2019

Restructuring and Related Activities [Abstract]

Summary of Restructuring Accrual Activity

Restructuring liability activity in 2019, 2018 and 2017 was as follows:

	Employee Termination						Other						Total
(Millions of dollars)	Bard			Other Initiatives (a)			Bard (b)			Other Initiatives (a)			Bard			Other Initiatives (a)
Balance at September 30, 2016	$	—		$	67		$	—		$	2		$	—		$	69
Charged to expense	—			27			—			58			—			85
Cash payments	—			(45		)	—			(12		)	—			(57		)
Non-cash settlements	—			—			—			(9		)	—			(9		)
Other adjustments	—			—			—			(33		)	—			(33		)
Balance at September 30, 2017	$	—		$	49		$	—		$	6		$	—		$	55
Charged to expense	136			30			156			22			292			52
Cash payments	(103		)	(56		)	(3		)	(23		)	(106		)	(79		)
Non-cash settlements	—			—			(153		)	(1		)	(153		)	(1		)
Balance at September 30, 2018	$	33		$	23		$	—		$	4		$	33		$	27
Charged to expense	23			29			95			33			118			62
Cash payments	(34		)	(21		)	(5		)	(31		)	(39		)	(52		)
Non-cash settlements	—			—			(89		)	(3		)	(89		)	(3		)
Balance at September 30, 2019	$	22		$	31		$	1		$	3		$	23		$	34

(a) Restructuring costs in 2019, 2018 and 2017 included expenses related to the Company's acquisition of CareFusion in fiscal year 2015 and other initiatives.

(b)

Expenses in 2019 and 2018 largely represented the costs associated with the conversion of certain pre-acquisition equity awards of Bard which, to encourage post-acquisition employee retention, were converted to BD equity awards with substantially the same terms and conditions as were applicable under such Bard awards immediately prior to the acquisition date.  Expenses in 2018 also included costs relating to Bard’s pension plan, partially offset by a gain on the sale of the Company's soft tissue core needle biopsy product line which was recorded in the second quarter of fiscal year 2018.